NAMS · NewAmsterdam Pharma Company N.V.

The departure of Louise Kooij as Chief Accounting Officer, effective August 31, 2026, involves a separation agreement that provides substantial retention incentives through the transition period. Key compensation includes a full year of base salary in a lump sum, a pro-rated target bonus reflecting performance through the separation date, and payment for accrued vacation under Dutch law. Notably, the extension of equity vesting to January 10, 2027, and a one-year post-vesting exercise window for options to February 10, 2027, offer continuity for her unvested awards. These terms, alongside restrictive covenants on confidentiality, competition, and disparagement plus a full release of claims, mitigate transition risks for investors while ensuring compliance and discretion.